Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-043524
Filing Date
2025-05-15
Accepted
2025-05-14 19:05:31
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241720-10q_bioess.htm   iXBRL 10-Q 511847
2 CERTIFICATION ea0241720ex31-1_bioess.htm EX-31.1 16907
3 CERTIFICATION ea0241720ex32-1_bioess.htm EX-32.1 9886
4 GRAPHIC image_001.jpg GRAPHIC 15922
  Complete submission text file 0001213900-25-043524.txt   4087547

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bioe-20250331.xsd EX-101.SCH 39740
6 XBRL CALCULATION FILE bioe-20250331_cal.xml EX-101.CAL 57608
7 XBRL DEFINITION FILE bioe-20250331_def.xml EX-101.DEF 186891
8 XBRL LABEL FILE bioe-20250331_lab.xml EX-101.LAB 371285
9 XBRL PRESENTATION FILE bioe-20250331_pre.xml EX-101.PRE 202683
70 EXTRACTED XBRL INSTANCE DOCUMENT ea0241720-10q_bioess_htm.xml XML 318736
Mailing Address 2955 MAIN STREET STE 300 IRVINE CA 92614
Business Address 2955 MAIN STREET STE 300 IRVINE CA 92614 888-816-1494
Bio Essence Corp (Filer) CIK: 0001723059 (see all company filings)

EIN.: 943349551 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56263 | Film No.: 25947748
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)